trending Market Intelligence /marketintelligence/en/news-insights/trending/6lEoUl8DdZt1j3UohfufBQ2 content esgSubNav
In This List

Medtronic, Novo Nordisk team up to combine digital devices for diabetes

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Medtronic, Novo Nordisk team up to combine digital devices for diabetes

Medtronic PLC and Novo Nordisk A/S will collaborate to integrate data points from their respective digital devices to help diabetic patients manage their glucose intake more efficiently.

Under the agreement, data from Novo Nordisk's smart insulin pens will be merged into data obtained from Medtronic's continuous glucose monitoring, or CGM, devices.

"Our new agreement with Novo Nordisk will streamline the sharing of two of the most important pieces of information — glucose measurements and insulin dosed," Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic, said in a news release.

The CGM devices, like Medtronic's Guardian connect systems, feature predictive alerts that allow patients to be mindful of upcoming high and low glucose events. By integrating data from smart insulin pens into such devices, diabetic patients can significantly improve daily medication management, the companies said in a statement.